In the dynamic healthcare landscape, Alimetry is establishing itself as a pioneer by raising $18 million for its revolutionary wearable device. Intended for the diagnosis of gastric disorders, this non-invasive device promises to transform the way doctors identify and treat gastrointestinal discomfort. With solutions combining cutting-edge technology and ease of use, Alimetry is positioned to improve the quality of life of many patients facing uncomfortable symptoms.
Alimetry, a New Zealand startup, managed to raise $18 million for the development of its non-invasive portable device designed to facilitate the diagnosis of gastric disorders. This device, a flexible electrode applied to the abdomen, captures the electrical activity of the stomach, allowing data analysis using artificial intelligence. Alimetry has already tested its product in more than 30 hospitals around the world and has obtained several approvals of the FDA. The company aims to focus on functional gastric disorders, while gradually opening up to others hospitals to expand access to its technologies.
The startup New Zealand Alimetry makes a significant advance in the field of digestive health with its portable device intended to effectively diagnose disorders gastric. Thanks to a fundraising of $18 million, the company aims to transform the care pathway for patients suffering from dysfunctions gastric, such as nausea or abdominal pain. The innovative product, both non-invasive and easy to use, could considerably simplify the diagnosis of various digestive pathologies.
Revolutionary technology for diagnosis
The portable device developed by Alimetry uses a flexible electrode applied to the patient’s abdomen, making it possible to capture the electrical activity generated by the digestive tract. Thanks to an analysis based on the cloud and integrating artificial intelligence algorithms, the data collected is transformed into biosensors relevant clinics. The goal is to provide doctors with more effective tools for making a diagnosis, particularly for disorders neuromuscular affecting the system gastric.
Development and application prospects
Alimetry anticipates that its product could not only be limited to stomach disorders, but also be applied in the field of pediatrics and for disorders affecting the stomach. colon. Tests carried out in more than 30 establishments hospital in New Zealand, the United States and the United Kingdom have already demonstrated the effectiveness of this technology. This fundraising will allow the startup to strengthen its research and obtain new health approvals, particularly with the FDA, thus paving the way for wider use of its device. Alimetry’s potential could significantly revolutionize the diagnosis and treatment of disorders gastric.
